Show simple item record

dc.contributor.authorSchrijver, Lieske H
dc.contributor.authorMooij, Thea M
dc.contributor.authorPijpe, Anouk
dc.contributor.authorSonke, Gabe S
dc.contributor.authorMourits, Marian JE
dc.contributor.authorAndrieu, Nadine
dc.contributor.authorAntoniou, Antonis
dc.contributor.authorEaston, Douglas
dc.contributor.authorEngel, Christoph
dc.contributor.authorGoldgar, David
dc.contributor.authorJohn, Esther M
dc.contributor.authorKast, Karin
dc.contributor.authorMilne, Roger L
dc.contributor.authorOlsson, Håkan
dc.contributor.authorPhillips, Kelly-Anne
dc.contributor.authorTerry, Mary Beth
dc.contributor.authorHopper, John L
dc.contributor.authorvan Leeuwen, Flora E
dc.contributor.authorRookus, Matti A
dc.date.accessioned2022-01-14T00:31:25Z
dc.date.available2022-01-14T00:31:25Z
dc.date.issued2022-04-11
dc.identifier.issn0027-8874
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/332703
dc.description.abstractBACKGROUND: To help BRCA1 and 2 mutation carriers make informed decisions regarding use of combined-type oral contraceptive preparation (COCP), absolute risk-benefit estimates are needed for COCP-associated cancer. METHODS: For a hypothetical cohort of 10 000 women, we calculated the increased or decreased cumulative incidence of COCP-associated (breast, ovarian, endometrial) cancer, examining 18 scenarios with differences in duration and timing of COCP use, uptake of prophylactic surgeries, and menopausal hormone therapy. RESULTS: COCP use initially increased breast cancer risk and decreased ovarian and endometrial cancer risk long term. For 10 000 BRCA1 mutation carriers, 10 years of COCP use from age 20 to 30 years resulted in 66 additional COCP-associated cancer cases by the age of 35 years, in addition to 625 cases expected for never users. By the age of 70 years such COCP use resulted in 907 fewer cancer cases than the expected 9093 cases in never users. Triple-negative breast cancer estimates resulted in 196 additional COCP-associated cases by age 40 years, in addition to the 1454 expected. For 10 000 BRCA2 mutation carriers using COCP from age 20 to 30 years, 80 excess cancer cases were estimated by age 40 years in addition to 651 expected cases; by the age of 70 years, we calculated 382 fewer cases compared with the 6156 cases expected. The long-term benefit of COCP use diminished after risk-reducing bilateral salpingo-oophorectomy followed by menopausal hormone therapy use. CONCLUSION: Although COCP use in BRCA1 and BRCA2 mutation carriers initially increases breast, ovarian, and endometrial cancer risk, it strongly decreases lifetime cancer risk. Risk-reducing bilateral salpingo-oophorectomy and menopausal hormone therapy use appear to counteract the long-term COCP-benefit.
dc.description.sponsorshipPink-Ribbon/Dutch-Cancer-Society (2014-187.WO76) and Transcan-JT (2012/Cancer-12-054)
dc.publisherOxford University Press (OUP)
dc.rightsAll Rights Reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.titleOral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
dc.typeArticle
dc.publisher.departmentDepartment of Public Health And Primary Care, Cancer Genetic Epidemiology
dc.date.updated2022-01-13T10:34:20Z
prism.publicationNameJ Natl Cancer Inst
dc.identifier.doi10.17863/CAM.80147
dcterms.dateAccepted2022-01-10
rioxxterms.versionofrecord10.1093/jnci/djac004
rioxxterms.versionAM
dc.contributor.orcidSchrijver, Lieske H [0000-0003-2580-2096]
dc.contributor.orcidSonke, Gabe S [0000-0001-8088-9628]
dc.contributor.orcidMourits, Marian JE [0000-0003-2385-2639]
dc.contributor.orcidAndrieu, Nadine [0000-0001-8820-5550]
dc.contributor.orcidAntoniou, Antonis [0000-0001-9223-3116]
dc.contributor.orcidEaston, Douglas [0000-0003-2444-3247]
dc.contributor.orcidEngel, Christoph [0000-0002-7247-282X]
dc.contributor.orcidJohn, Esther M [0000-0003-3259-8003]
dc.contributor.orcidKast, Karin [0000-0001-6531-755X]
dc.contributor.orcidMilne, Roger L [0000-0001-5764-7268]
dc.contributor.orcidPhillips, Kelly-Anne [0000-0002-0475-1771]
dc.identifier.eissn1460-2105
rioxxterms.typeJournal Article/Review
cam.issuedOnline2022-01-20
cam.orpheus.successTue Feb 01 19:02:44 GMT 2022 - Embargo updated
cam.depositDate2022-01-13
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
rioxxterms.freetoread.startdate2023-01-20


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record